Induction of CYP2D6 in pregnancy

Clinical Pharmacology and Therapeutics

Volumn 62, Issue 4, 1997, Pages 400-407

  Wadelius, Mia ^a   Darj, Elisabeth ^a   Frenne, Gunilla ^a   Rane, Anders ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 ISOENZYME; DEBRISOQUINE; DEXTROMETHORPHAN; DEXTRORPHAN; METOPROLOL;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; ENZYME INDUCTION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; PREGNANCY; PRIORITY JOURNAL; THIRD TRIMESTER PREGNANCY;

ADULT; ANTITUSSIVE AGENTS; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DEXTROMETHORPHAN; DEXTRORPHAN; DNA; ENZYME INDUCTION; FEMALE; GENOTYPE; HUMANS; OXIDOREDUCTASES, N-DEMETHYLATING; PHENOTYPE; PREGNANCY;

EID: 0030699314     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(97)90118-1     Document Type: Article

References (32)

1. Brøsen K. The pharmacogenetics of the selective serotonin reuptake inhibitors. Clin Investig 1993;12:1002-9.
2. Dahl ML, Bertilsson L. Genetically variable metabolism of antidepressants and neuroleptic drugs in man. Pharmacogenetics 1993;3:61-70.
3. Lennard MS. The polymorphic oxidation of beta-adrenoceptor antagonists. Pharmacol Ther 1989;41: 461-77.
4. Maghoub A, Idle JR, Dring LG, Lancaster R, Smith RL. Polymorphic hydroxylation of debrisoquine in man. Lancet 1977;2:584-6.
5. Heim M, Meyer UA. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet 1990;336:529-32.
6. Gonzalez FJ, Meyer UA. Molecular genetics of the debrisoquin-sparteine polymorphism. Clin Pharmacol Ther 1991;50:233-8.
7. Johansson I, Lundqvist E, Bertilsson L, Dahl ML, Sjöqvist F, Ingelman-Sundberg M. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA 1993;90: 11825-9.
8. Eichelbaum M, Mineshita S, Ohnhaus EE, Zekorn C. The influence of enzyme induction on polymorphic sparteine oxidation. Br J Clin Pharmacol 1986;22:49-53.
9. Högstedt S, Lindberg B, Rane A. Increased oral clearance of metoprolol in pregnancy. Eur J Clin Pharmacol 1983;24:217-20.
10. Högstedt S, Lindberg B, Peng DR, Regårdh CG, Rane A. Pregnancy-induced increase in metoprolol metabolism. Clin Pharmacol Ther 1985;37:688-92.
11. Lennard MS, Silas JH, Freestone S, Ramsay LE, Tucker GT, Woods HF. Oxidation phenotype: a major determinant of metoprolol metabolism and response. N Engl J Med 1982;307:1558-60.
12. McGourty JC, Silas JH, Lennard MS, Tucker GT, Woods HF. Metoprolol metabolism and debrisoquine oxidation polymorphism: population and family studies. Br J Clin Pharmacol 1985;20:555-66.
13. Gustincich S, Manfioletti G, Del Sal G, Schneider C. A fast method for high-quality genomic DNA extraction from whole human blood. Biotechniques 1991; 11:298-302.
14. Kagimoto M, Heim M, Kagimoto K, Zeugin T, Meyer UA. Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. J Biol Chem 1990;265:17209-14.
15. Wolf CR, Moss JE, Miles JS, Gough AC, Spurr NK. Detection of debrisoquine hydroxylation phenotypes. Lancet 1990;336:1452-3.
16. Smith CAD, Gough AC, Leigh PN, Summers BA, Harding AE, Maraganore DM, et al. Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet 1992;339:1375-7.
17. Gough A, Miles JS, Spurr NK, Moss JE, Gaedigk A, Eichelbaum M, et al. Identification of the primary gene defect at the cytochrome P450 CYP2D locus. Nature 1990;347:773-6.
18. Jacqz-Aigrain E, Funck-Brentano C, Cresteil T. CYP2D6- and CYP3A-dependent metabolism of dextromethorphan in humans. Pharmacogenetics 1993;3: 197-204.
19. Capon DA, Bochner F, Kerry N, Mikus G, Danz C, Somogyi AA. The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans. Clin Pharmacol Ther 1996;60:295-307.
20. Mortimer Ö, Lindström B, Laurell H, Bergman U, Rane A. Dextromethorphan: polymorphic serum pattern of the O-demethylated and didemethylated metabolites in man. Br J Clin Pharmacol 1989;27:223-7.
21. Kallio J, Lindberg R, Huupponen R, Iisalo E. Debrisoquine oxidation in a Finnish population: the effect of oral contraceptives on the metabolic ratio. Br J Clin Pharmacol 1988;26:791-5.
22. Llerena A, Cobaleda J, Martínez C, Benítez J. Interethnic differences in drug metabolism: influence of genetic and environmental factors on debrisoquine hydroxylation phenotype. Eur J Drug Metab Pharmacokinet 1996;21:129-38.
23. Pepper JM, Lennard MS, Tucker GT, Woods HF. Effect of steroids on the cytochrome P4502D6-catalysed metabolism of metoprolol. Pharmacogenetics 1991;1:119-22.
24. Ellis SW, Hayhurst GP, Smith G, Lightfoot T, Wong MM, Simula AP, et al. Evidence that aspartic acid 301 is a critical substrate-contact residue in the active site of cytochrome P450 2D6. J Biol Chem 1995;270:29055-8.
25. Kerr BM, Thummel KE, Wurden CJ, Klein SM, Kroetz DL, Gonzalez FJ, et al. Human liver carbamazepine metabolism: role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. Biochem Pharmacol 1994; 47:1969-79.
26. Gleiter CH, Gundert-Remy U. Gender differencies in pharmacokinetics. Eur J Drug Metab Pharmacokinet 1996;21:123-8.
27. Ladona MG, Park SS, Gelboin HV, Hammar L, Rane A. Monoclonal antibody directed detection of cytochrome P-450 (PCN) in human fetal liver. Biochem Pharmacol 1988;37:4735-41.
28. Ladona MG, Lindström B, Thyr C, Peng DR, Rane A. Differential foetal development of the O-and N-demethylation of codeine and dextromethorphan in man. Br J Clin Pharmacol 1991;32:295-302.
29. Hakkola J, Paasanen M, Purkunen R, Saarikoski S, Pelkonen O, Maenpaa J, et al. Expression of xenobiotic-metabolizing cytochrome P450 forms in human adult and fetal liver. Biochem Pharmacol 1994;48:59-64.
30. Hakkola J, Pasanen M, Hukkanen J, Pelkonen O, Maenpaa J, Edwards RJ, et al. Expression of xenobiotic-metabolizing cytochrome P450 forms in human full-term placenta. Biochem Pharmacol 1996;51:403-11.
31. Hakkola J, Raunio H, Purkunen R, Pelkonen O, Saarikoski S, Cresteil T, et al. Detection of cytochrome P450 gene expression in human placenta in first trimester of pregnancy. Biochem Pharmacol 1996;52:379-83.
32. Tréluyer JM, Jacqz-Aigrain E, Alvarez F, Cresteil T. Expression of CYP2D6 in developing human liver. Eur J Biochem 1991;202:583-8.